Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

204 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Quintás-Cardama A, Kantarjian H, Cortes J. Quintás-Cardama A, et al. Nat Rev Clin Oncol. 2009 Sep;6(9):535-43. doi: 10.1038/nrclinonc.2009.112. Epub 2009 Aug 4. Nat Rev Clin Oncol. 2009. PMID: 19652654 Review.
p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, Hornbaker MJ, Qi Y, Su X, Pageon LR, Quintas-Cardama A, Post SM. Lee HJ, et al. Blood Cancer J. 2016 Jun 10;6(6):e434. doi: 10.1038/bcj.2016.41. Blood Cancer J. 2016. PMID: 27284738 Free PMC article.
Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Quintás-Cardama A, Kantarjian H, Cortes J. Quintás-Cardama A, et al. Drugs Today (Barc). 2012 Mar;48(3):177-88. doi: 10.1358/dot.2012.48.3.1750274. Drugs Today (Barc). 2012. PMID: 22462037 Review.
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.
Hughes TP, Saglio G, Quintás-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A. Hughes TP, et al. Leukemia. 2015 Sep;29(9):1832-8. doi: 10.1038/leu.2015.168. Epub 2015 Jun 29. Leukemia. 2015. PMID: 26118315 Free PMC article. Clinical Trial.
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.
Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J. Talpaz M, et al. Leukemia. 2013 Apr;27(4):803-12. doi: 10.1038/leu.2012.313. Epub 2012 Nov 7. Leukemia. 2013. PMID: 23238589 Free PMC article. Review.
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Quintás-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, Gilliland DG, Lee F, Cortes J, Kantarjian H, Garcia-Manero G. Quintás-Cardama A, et al. Leukemia. 2008 Jun;22(6):1117-24. doi: 10.1038/leu.2008.80. Epub 2008 Apr 10. Leukemia. 2008. PMID: 18401417
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Quintás-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S. Quintás-Cardama A, et al. Leukemia. 2008 May;22(5):965-70. doi: 10.1038/leu.2008.91. Epub 2008 Apr 3. Leukemia. 2008. PMID: 18385750 Free PMC article. Clinical Trial.
Experimental non-ATP-competitive therapies for chronic myelogenous leukemia.
Quintás-Cardama A. Quintás-Cardama A. Leukemia. 2008 May;22(5):932-40. doi: 10.1038/leu.2008.47. Epub 2008 Mar 6. Leukemia. 2008. PMID: 18323796 Review.
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Pan J, Quintás-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S. Pan J, et al. Leukemia. 2007 Jul;21(7):1395-404. doi: 10.1038/sj.leu.2404714. Epub 2007 May 10. Leukemia. 2007. PMID: 17495975
204 results
Jump to page
Feedback